Neurogene (NGNE)
NASDAQ:NGNE
Want to see NGNE full AI Analyst Report?
Top Page
Neurogene
(NASDAQ:NGNE)
Select Model
Select Model
Rating:55Neutral
Price Target:
$27.00
▼(-3.05% Downside)
Action:Reiterated
Date:06/08/26
The score is anchored by solid balance-sheet strength but weighed down by ongoing, widening losses and heavy cash burn. Technicals are neutral-to-weak in the near term, valuation is hard to support given negative earnings and no dividend, while recent corporate updates provide a meaningful positive offset via clinical execution and commercial build-out.
Positive Factors
Balance Sheet Strength
Neurogene's low leverage and sizable equity provide durable financial flexibility for a development-stage biotech. A ~0.04 debt/equity and meaningful asset base reduce refinancing risk, support continued R&D and registrational activities, and preserve optionality for partnerships or commercialization execution if clinical results are positive.
Negative Factors
Cash Burn & Negative Cash Flow
Persistently deep negative operating and free cash flow means Neurogene is consuming cash rapidly. Sustained high burn will pressure the balance sheet over months, likely necessitating dilutive financings or partnerships, and constrains strategic flexibility for prolonged follow-up, manufacturing scale-up, or parallel development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Neurogene's low leverage and sizable equity provide durable financial flexibility for a development-stage biotech. A ~0.04 debt/equity and meaningful asset base reduce refinancing risk, support continued R&D and registrational activities, and preserve optionality for partnerships or commercialization execution if clinical results are positive.
Read all positive factors
Neurogene (NGNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$471.84M
Dividend YieldN/A
Average Volume (3M)225.72K
Price to Earnings (P/E)―
Beta (1Y)3.03
Revenue Growth-100.00%
EPS Growth-7.33%
CountryUS
Employees107
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.03
Shares Outstanding15,801,901
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.12
Enterprise Value/Ebitda-3.65
Forecast
1Y Price Target
$80.00Price Target Upside187.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.44
Revenue Forecast (FY)N/A
Neurogene Business Overview & Revenue Model
Company Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-4...
How the Company Makes Money
Neurogene does not have publicly disclosed recurring commercial product revenue, and as a clinical-stage biotech it primarily funds operations through capital raises (e.g., issuing equity in public or private financings) and, when applicable, non-...
Neurogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 925.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -38.25M | -3.19M | -2.32M | -3.26M | -3.20M | -42.26M |
| EBITDA | -95.45M | -87.25M | -71.89M | -33.01M | -51.99M | -49.57M |
| Net Income | -98.64M | -90.35M | -75.14M | -36.32M | -55.19M | -50.52M |
Balance Sheet | ||||||
| Total Assets | 263.14M | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M |
| Cash, Cash Equivalents and Short-Term Investments | 243.18M | 269.01M | 312.40M | 197.16M | 82.02M | 70.54M |
| Total Debt | 9.13M | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M |
| Total Liabilities | 25.36M | 23.72M | 25.36M | 36.55M | 10.64M | 193.36M |
| Stockholders Equity | 237.78M | 264.89M | 310.38M | 186.02M | 98.63M | -91.88M |
Cash Flow | ||||||
| Free Cash Flow | -82.61M | -78.36M | -71.41M | -51.74M | -55.05M | -64.77M |
| Operating Cash Flow | -81.94M | -77.17M | -70.60M | -51.42M | -52.82M | -46.40M |
| Investing Cash Flow | 106.01M | 14.00M | -125.26M | 25.64M | -2.23M | -18.37M |
| Financing Cash Flow | 30.68M | 30.43M | 184.07M | 92.48M | 66.53M | 51.06M |
Neurogene Technical Analysis
Positive
27.85
Price Trends
27.25
Positive
23.51
Positive
23.02
Positive
Market Momentum
0.47
Negative
56.31
Neutral
83.26
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Positive. The current price of 27.85 is above the 20-day moving average (MA) of 27.78, above the 50-day MA of 27.25, and above the 200-day MA of 23.02, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 56.31 is Neutral, neither overbought nor oversold. The STOCH value of 83.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NGNE.
Neurogene Risk Analysis
Neurogene disclosed 88 risk factors in its most recent earnings report. Neurogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neurogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $471.84M | -6.64 | -37.88% | ― | -100.00% | -7.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $330.64M | -3.72 | -107.19% | ― | ― | ― | |
49 Neutral | $348.12M | -1.99 | -57.01% | ― | ― | -28.75% | |
48 Neutral | $155.96M | -1.25 | -80.56% | ― | ― | 59.42% | |
46 Neutral | $762.40M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
40 Underperform | $77.87M | -1.25 | -2748.16% | ― | ― | 43.68% |
* Healthcare Sector Average
NGNE
Neurogene
29.35
10.93
59.34%
SLN
Silence Therapeutics
6.71
1.34
24.95%
AVIR
Atea Pharmaceuticals
4.26
1.05
32.71%
ELTX
Elicio Therapeutics
2.76
-5.19
-65.28%
VOR
Vor Biopharma
14.11
9.99
242.48%
TNYA
Tenaya Therapeutics
0.68
0.11
18.47%
Neurogene Corporate Events
Business Operations and StrategyProduct-Related Announcements
Neurogene Completes Dosing in Embolden Rett Trial
Positive
Jun 8, 2026
On June 8, 2026, Neurogene announced that it had successfully completed dosing in its Embolden registrational trial of NGN-401 for Rett syndrome, exceeding its original enrollment target by treating 25 participants due to strong patient demand. Th...
Executive/Board ChangesShareholder Meetings
Neurogene Stockholders Vote on Directors and Executive Pay
Neutral
Jun 4, 2026
On June 3, 2026, Neurogene Inc. held its 2026 Annual Meeting of Stockholders, where a quorum of approximately 72.92% of eligible voting power was present in person or by proxy. Stockholders elected Class III directors Robert Baffi and Rohan Paleka...
Business Operations and StrategyExecutive/Board Changes
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization
Positive
Apr 20, 2026
On April 20, 2026, Neurogene’s board expanded to seven members and appointed President and Chief Financial Officer Christine Mikail as a Class II director with a term through the 2028 annual meeting. The move formalizes Mikail’s influe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.